Interaction Checker
This website was last updated on 1st June 2022 and interactions and content may have changed.
The Cancer Drug Interactions website was set up in 2017 and is a joint venture between Radboud University Medical Centre in Nijmegen, Netherlands and the University of Liverpool, UK.
Dr Nielka van Erp
(Clinical Leadership)
Dr Frank Jansman
(Scientific/Clinical Leadership)
Frank is a Hospital Pharmacist and Clinical Pharmacologist at the Deventer Teaching Hospital and at the University Groningen. He is particularly interested in pharmacotherapy and pharmaceutical care of cancer patients and in clinical toxicology. Frank is chairman of the Dutch Working Group for Interactions Anticancer Drugs (Dutch Association of Hospital Pharmacists, Dutch Society for Medical Oncology, Haemato Oncology Foundation for Adults in the Netherlands, Dutch Society of Clinical Pharmacology and Biopharmacy) and chairman of the Dutch Working Group for Pharmacotherapy and Drug Information (Royal Dutch Pharmacists Association).
Prof David Burger
(Scientific Leadership)
David is a Professor of Clinical Pharmacy, Radboud University Nijmegen and is (co-) author of more than 350 publications in this field. The topics of his interest are drug-drug interactions, paediatric pharmacology, therapeutic drug monitoring, and operational research in resource-limited countries. David is member of the Editorial Board of www.hiv-druginteractions.org and www.hep-druginteractions.org and member of the Organizing Committee of the annual International Workshop on Clinical Pharmacology of Antiviral Therapy.
Dr Rob ter Heine
(Clinical Leadership)
Rob is a Hospital Pharmacist, Clinical Pharmacologist and Head of the Clinical Trials Unit in the Department of Pharmacy at Radboud University Medical Centre. Rob specializes in quantitative pharmacology and applied pharmacometrics with a focus on clinical pharmacology of drugs in lung oncology.
Dr Elise Smolders
(Scientific/Clinical Leadership)
Elise is a Hospital Pharmacist and Clinical Pharmacologist responsible for the pharmaceutical supply chain in the Department of Pharmacy at Radboud University Medical Centre. She obtained a PhD on the clinical pharmacology of direct-acting antivirals used for hepatitis C treatment which mainly focused on drug-drug interactions. She recently switched to the field of clinical pharmacology of oncology drugs.
Leila-Sophie Otten
(Content Development)
Leila-Sophie obtained her PharmD at Utrecht University and is a PhD candidate and Pharmacist in the Departments of Pharmacy and Pulmonology at Radboud University Medical Centre. Her research focuses on personalization and optimization of lung cancer treatment. Leila-Sophie develops content for the website, primarily looking at drug-drug interactions with lung cancer treatment.
Prof Saye Khoo
(Scientific Leadership)
Saye is a Professor of Clinical Pharmacology at the University of Liverpool and Honorary Consultant Physician, Royal Liverpool and Broadgreen University Hospitals NHS Trust. His primary research interests centre on the pharmacology of HIV treatment failure, including investigation of drug interactions, the role of therapeutic drug monitoring, population pharmacokinetic modelling, molecular characterisation of drug metabolism and disposition pathways and the role of host genetic variability in influencing drug exposure and response.
Along with Em Prof David Back, Saye founded and leads the sister sites www.hiv-druginteractions.org and www.hep-druginteractions.org.
Jasmine Martin
(Development Manager)
Jasmine obtained a BSc (Hons) degree in Pharmacology from the University of Liverpool in 2016 and, after completing a Master degree by research, she joined the website team in August 2017 working mainly on the cancer drug interactions website. In March 2020, Jasmine took up the post of Development Manager for all the websites (HIV, HEP, COVID and Cancer) and is responsible for developing partnerships and projects which support our mission and ethos.